Phathom Pharmaceuticals, Inc. ((PHAT)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: Phathom Pharmaceuticals, Inc. is conducting a Phase 2 study titled A Phase 2, Randomized, Double-Blind, Multi-Center Study in Adult Subjects With Eosinophilic Esophagitis (EoE) to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate the Safety and Efficacy of Vonoprazan 20 mg Up to 24 Weeks. The study aims to assess the efficacy of vonoprazan 20 mg once daily compared to a placebo in reducing eosinophilic histologic response in adult participants with EoE.
Intervention/Treatment: The study tests the drug vonoprazan, administered orally as a 20 mg tablet. It aims to evaluate its effectiveness in treating EoE by comparing it to a placebo.
Study Design: This is a randomized, double-blind, multi-center study with a parallel intervention model. Both participants and investigators are masked. The primary purpose is treatment, focusing on the safety and efficacy of vonoprazan over a 24-week period.
Study Timeline: The study began on February 24, 2025. The primary completion date is not specified, but the latest update was submitted on October 23, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: The ongoing study could significantly impact Phathom Pharmaceuticals’ stock performance, as positive results may boost investor confidence and market value. Given the competitive landscape in EoE treatments, successful outcomes could position vonoprazan as a leading option, influencing industry dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.